146 related articles for article (PubMed ID: 18058255)
1. Inhibition on Hepatitis B virus in vitro of recombinant MAP30 from bitter melon.
Fan JM; Zhang Q; Xu J; Zhu S; Ke T; Gao DF; Xu YB
Mol Biol Rep; 2009 Feb; 36(2):381-8. PubMed ID: 18058255
[TBL] [Abstract][Full Text] [Related]
2. Anti-HIV and anti-tumor activities of recombinant MAP30 from bitter melon.
Lee-Huang S; Huang PL; Chen HC; Huang PL; Bourinbaiar A; Huang HI; Kung HF
Gene; 1995 Aug; 161(2):151-6. PubMed ID: 7665070
[TBL] [Abstract][Full Text] [Related]
3. [Expression of recombinant ribosome inactivating protein MAP30 in E.coli and its biological activity].
Zhang LL; Ding Q; Zhan JB
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2010 May; 39(3):264-71. PubMed ID: 20544988
[TBL] [Abstract][Full Text] [Related]
4. MAP30 protein from Momordica charantia is therapeutic and has synergic activity with cisplatin against ovarian cancer in vivo by altering metabolism and inducing ferroptosis.
Chan DW; Yung MM; Chan YS; Xuan Y; Yang H; Xu D; Zhan JB; Chan KK; Ng TB; Ngan HY
Pharmacol Res; 2020 Nov; 161():105157. PubMed ID: 32814169
[TBL] [Abstract][Full Text] [Related]
5. Preparation of an antitumor and antivirus agent: chemical modification of α-MMC and MAP30 from Momordica Charantia L. with covalent conjugation of polyethyelene glycol.
Meng Y; Liu S; Li J; Meng Y; Zhao X
Int J Nanomedicine; 2012; 7():3133-42. PubMed ID: 22802682
[TBL] [Abstract][Full Text] [Related]
6. Α-MMC and MAP30, two ribosome-inactivating proteins extracted from Momordica charantia, induce cell cycle arrest and apoptosis in A549 human lung carcinoma cells.
Fan X; He L; Meng Y; Li G; Li L; Meng Y
Mol Med Rep; 2015 May; 11(5):3553-8. PubMed ID: 25573293
[TBL] [Abstract][Full Text] [Related]
7. Expression and purification of a recombinant ELRL-MAP30 with dual-targeting anti-tumor bioactivity.
Chen WW; Zhang HR; Huang ZG; Zhou ZY; Lou QW; Jiang XY; Zhu ZH
Protein Expr Purif; 2021 Sep; 185():105893. PubMed ID: 33933613
[TBL] [Abstract][Full Text] [Related]
8. [Inhibition of momordica anti-HIV protein of MAP30 on HBeAg expression by laser scanning confocal microscopy].
Wang JP; Wang LX; Sun YT; Bai XF; Li JG; Chen WH; Sun L; Luo KX
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2003 Mar; 19(2):183-4. PubMed ID: 15151762
[TBL] [Abstract][Full Text] [Related]
9. Curcumin inhibits hepatitis B virus infection by down-regulating cccDNA-bound histone acetylation.
Wei ZQ; Zhang YH; Ke CZ; Chen HX; Ren P; He YL; Hu P; Ma DQ; Luo J; Meng ZJ
World J Gastroenterol; 2017 Sep; 23(34):6252-6260. PubMed ID: 28974891
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the replication of hepatitis B virus in vitro by emodin.
Shuangsuo D; Zhengguo Z; Yunru C; Xin Z; Baofeng W; Lichao Y; Yan'an C
Med Sci Monit; 2006 Sep; 12(9):BR302-6. PubMed ID: 16940925
[TBL] [Abstract][Full Text] [Related]
11. Expression of Momordica charantia MAP30 and its antitumor effect on bladder cancer cells.
Hlin H; Zhi-Guo Z; Cong-Hui H; Yan Z; Qing L; Bo J; Hou-Guang H; Jun-Jie Z; Pei-Ying Z
Minerva Urol Nefrol; 2016 Jun; 68(3):275-81. PubMed ID: 25517785
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of hepatitis B virus replication by pokeweed antiviral protein in vitro.
He YW; Guo CX; Pan YF; Peng C; Weng ZH
World J Gastroenterol; 2008 Mar; 14(10):1592-7. PubMed ID: 18330954
[TBL] [Abstract][Full Text] [Related]
13. Immunoaffinity purification of α-momorcharin from bitter melon seeds (Momordica charantia).
Yao X; Li J; Deng N; Wang S; Meng Y; Shen F
J Sep Sci; 2011 Nov; 34(21):3092-8. PubMed ID: 21994203
[TBL] [Abstract][Full Text] [Related]
14. Effects of recombinant MAP30 on cell proliferation and apoptosis of human colorectal carcinoma LoVo cells.
Fan JM; Luo J; Xu J; Zhu S; Zhang Q; Gao DF; Xu YB; Zhang GP
Mol Biotechnol; 2008 May; 39(1):79-86. PubMed ID: 18246454
[TBL] [Abstract][Full Text] [Related]
15. Potentiation of anti-HIV activity of anti-inflammatory drugs, dexamethasone and indomethacin, by MAP30, the antiviral agent from bitter melon.
Bourinbaiar AS; Lee-Huang S
Biochem Biophys Res Commun; 1995 Mar; 208(2):779-85. PubMed ID: 7695636
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the integrase of human immunodeficiency virus (HIV) type 1 by anti-HIV plant proteins MAP30 and GAP31.
Lee-Huang S; Huang PL; Huang PL; Bourinbaiar AS; Chen HC; Kung HF
Proc Natl Acad Sci U S A; 1995 Sep; 92(19):8818-22. PubMed ID: 7568024
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of hepatitis B virus DNA replicative intermediate forms by recombinant interferon-gamma.
Parvez MK; Sehgal D; Sarin SK; Basir SF; Jameel S
World J Gastroenterol; 2006 May; 12(19):3006-14. PubMed ID: 16718779
[TBL] [Abstract][Full Text] [Related]
18. Recombinant expression and purification of a MAP30-cell penetrating peptide fusion protein with higher anti-tumor bioactivity.
Lv Q; Yang XZ; Fu LY; Lu YT; Lu YH; Zhao J; Wang FJ
Protein Expr Purif; 2015 Jul; 111():9-17. PubMed ID: 25797209
[TBL] [Abstract][Full Text] [Related]
19. Construction and expression of eukaryotic plasmids containing lamivudine-resistant or wild-type strains of Hepatitis B Virus genotype C.
Xu WZ; Fang Y; Li D; Wang Y; Shang QL; Li GQ; Teng X; Gu HX
World J Gastroenterol; 2008 Jun; 14(23):3733-8. PubMed ID: 18595141
[TBL] [Abstract][Full Text] [Related]
20. The heparin-binding domain of HB-EGF as an efficient cell-penetrating peptide for drug delivery.
Luo Z; Cao XW; Li C; Wu MD; Yang XZ; Zhao J; Wang FJ
J Pept Sci; 2016 Nov; 22(11-12):689-699. PubMed ID: 27739168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
